

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



山東新華製藥股份有限公司

**Shandong Xinhua Pharmaceutical Company Limited**

*(a joint stock company established in the People's Republic of China with limited liability)*

(Stock Code: 00719)

## OVERSEAS REGULATORY ANNOUNCEMENT

This overseas regulatory announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Shandong Xinhua Pharmaceutical Company Limited will publish the “Announcement on Minoxidil Liniment having obtained Drug Registration Certificate” on CNINFO <http://www.cninfo.com.cn> (巨潮資訊網) on 27 August 2025. The English translation of the relevant document is hereby included for reference. If there is any inconsistency between the English version and the Chinese version, the Chinese version shall prevail.

By Order of the Board

**Shandong Xinhua Pharmaceutical Company Limited**

**He Tongqing**

*Chairman*

26 August 2025 Zibo, PRC

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. He Tongqing (*Chairman*)

Mr. Xu Wenhui

Mr. Hou Ning

Independent Non-executive Directors:

Mr. Pan Guangcheng

Mr. Zhu Jianwei

Mr. Ling Peixue

Ms. Cheung Ching Ching, Daisy

Non-executive Directors:

Mr. Xu Lie

Mr. Zhang Chengyong

**Shandong Xinhua Pharmaceutical Company Limited**  
**Announcement on Minoxidil Liniment having obtained Drug Registration Certificate**

The Company (hereinafter referred to as “**Xinhua Pharmaceutical**” or the “**Company**”) and its board of directors confirm that the contents of this announcement are true, accurate and complete without any false information, misleading statements or material omissions.

The Company has recently received the *Drug Registration Certificate* (药品注册证书) for its Minoxidil Liniment (hereinafter referred to as the “**Product**”) approved and issued by the National Medical Products Administration. Relevant information is now announced as follows:

**I. Basic information**

Drug name:	Minoxidil Liniment
Dosage form:	Liniment
Specifications:	2% (60ml:1.2g); 5% (60ml:3g)
Drug category:	Over-the-counter drugs
Registered classification:	Class 3 chemicals
Applicant:	Shandong Xinhua Pharmaceutical Company Limited
Application matter:	Drug registration (Domestic production)
Case number:	CYHS2302643, CYHS2302644
Drug approval number:	National Medicine Zhunzi (国药准字) H20255138;H20255139
Notification number:	2025S02503, 2025S02504
Review conclusion:	In accordance with the <i>Pharmaceutical Administration Law of the People's Republic of China</i> (中华人民共和国药品管理法) and relevant regulation, upon review, the Product conforms with the applicable requirements of drug registration, and the drug registration certificate has been issued. Agree to manage this product as a (Class A) OTC drug. The standard of quality, product instructions, labels as well as production process concerning the Product shall be consummated in accordance with relevant documentation. The product should undergo a GMP compliance check before it is launched.

**II. Other relevant information**

In October 2023, Xinhua Pharmaceutical submitted application materials to the Center for Drug Evaluation of the State Drug Administration (药品审评中心) (CDE) concerning marketing of Minoxidil Liniment and the application materials were accepted. In August 2025, Xinhua Pharmaceutical obtained the *Drug Registration Certificate*, and the review conclusion was that the Product shall be approved for registration.

The Product is used for the treatment of male pattern baldness and alopecia areata. According to relevant statistics, sales of Minoxidil Liniment in China’s public medical institutions amounted to approximately RMB

2.36 billion in 2024.

### **III. Impact on the Company and risk warning**

The obtaining by Xinhua Pharmaceutical of approval in connection with its Minoxidil Liniment in August 2025 will serve to enrich the Company's product portfolio and enhance its overall competitiveness.

The pharmaceutical sales business is susceptible to changes in domestic pharmaceutical industry policies, bidding and procurement processes, changes in the market environment and other factors, and is subject to uncertainty. Investors are advised to invest sensibly and pay attention to investment risks.

By Order of the Board  
**Shandong Xinhua Pharmaceutical Company  
Limited**  
26 August 2025